Document:

Exhibit 10.10

 

POINT Biopharma Corp.

22 St. Clair Ave. East, Suite 1201,

Toronto, ON M4T 2S3

 

Michael Gottlieb

 

POINT Biopharma Corp. Employment Agreement

 

April 23, 2020

 

     

     

    

 

POINT Biopharma Corp. Employment Agreement

 

to be effective as of and from

the Effective Date (as defined below)

 

PRIVATE AND CONFIDENTIAL

 

Michael Gottlieb

579 Bedford Park Avenue

Toronto, ON M5M 1M5

 

Dear Michael:

 

		Re:	Terms
                                         of Employment of Michael Gottlieb (“you”
                                         or the “Employee”)
                                         with POINT Biopharma Corp. (the “Company”)

 

This Agreement (as defined below) sets out the terms and conditions
of your employment by the Company and will constitute your employment agreement.

 

For and in consideration of the promises herein and other valuable
consideration, the parties agree as follows:

 

Article 1 Interpretation

 

	1.1	Definitions

 

For the purposes of this Agreement:

 

		1.1.1	“$” means CDN dollars.

 

		1.1.2	“Affiliate” means with respect to
a Person, any Person that, directly or indirectly, Controls, is Controlled by, or is under common Control with such Person, including,
without limitation, any partner, officer, director, or member of such Person and any venture capital fund now or hereafter existing
that is Controlled by or under common Control with one or more general partners or shares the same management company or investment
manager with such Person, and including any parent or subsidiary company of such Person.

 

		1.1.3	“Agreement” means this employment
agreement and the exhibits hereto.

 

		1.1.4	“Base Salary” shall have the meaning
set out in Section 3.2 (Base Salary)

 

		1.1.5	“Business” means the business of
the Company described in Exhibit 1.1.5.

 

    2 

     

    

 

		1.1.6	“Business Information” means all
business information, including information regarding:

 

		.1	commercial strategies, business plans, business methods, corporate plans, management systems, finances, new business opportunities,
marketing or sales of any past, present or future product or service, including, without limitation, sales targets and statistics,
market share and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount
structures, advertising and promotional material;

 

		.2	financial information, compensation and investment arrangements, terms of agreements, financial structure, financial position,
financial results or other financial affairs, actual or proposed transactions or investments or other confidential information;
and

 

		.3	the name, address, telephone number, contact name and identity of each of the Key Contacts, the nature of their business operation,
and all confidential aspects of their business relationship or potential business relationship with the Company or any Affiliate
of the Company.

 

		1.1.7	“Cause” shall have the meaning set
out in Section 6.6 (Termination by Company for Cause).

 

		1.1.8	“Chief Commercial Officer” shall
have the meaning set out in Section 2.1 (Position and Duties).

 

		1.1.9	“Change of Control” shall be deemed
to have occurred if any of the following occurs after the Effective Date and before the Termination Date:

 

		.1	any “person” or
“group” (as such terms are defined below)
is or becomes the “beneficial owner” (as
defined below, except that a “person” or
“group” shall be deemed to have “beneficial
ownership” of all shares of capital stock or other equity interests if such person
or group has the right to acquire such shares or interests, whether such right is exercisable immediately or only after the passage
of time), directly or indirectly, in a transaction or series of related transactions, of shares of capital stock or other interests
(including partnership interests) of the Company then outstanding and normally entitled (without regard to the occurrence of any
contingency) to vote in the election of the directors, managers or similar supervisory positions (“Voting
Stock”) of the Company representing more than fifty percent (50%) of the total
voting power of all outstanding classes of Voting Stock; or;

 

		.2	a sale of substantially all of the assets of the Company; or

 

    3 

     

    

 

		.3	the Company enters into a merger, reverse-merger, amalgamation, arrangement, consolidation or other form of business combination, share exchange, reorganization, recapitalization, transfer or other similar transaction with another Person (whether or not the Company the surviving entity) and as a result of such transaction (a) the members of the board of directors of the Company immediately prior to such transaction constitute less than a majority of the members of the board of directors of the Company or such surviving entity immediately following such transaction or (b) the Persons that beneficially owned, directly or indirectly, the shares of Voting Stock of the Company immediately prior to such transaction cease to beneficially own, directly or indirectly, shares of Voting Stock of the Company representing at least a majority of the total voting power of all outstanding classes of Voting Stock of the surviving entity immediately following such transaction.

                                                                                 

                                                                                Notwithstanding the foregoing, a Change of Control
resulting from a Financing or from corporate changes between Company Affiliates is deemed not to be a Change of Control for the
purposes of this Agreement.

 

		1.1.10	“Confidential Information” means
all non-public information, knowledge, or data pertaining to the business, affairs and technology of the Company or any Affiliate
of the Company, including:

 

		.1	Technical Information and Business Information;

 

		.2	your Work Product; and

 

		.3	information secured by the Company from Persons subject to an obligation of confidentiality;

 

		and, in all cases, all copies and tangible embodiments
thereof, in whatever form or medium, all whether furnished or prepared before or after the Effective Date.

 

		1.1.11	“Control” or “Controls”
means, in relation to a corporation or a partnership, as the case may be:

 

		.1	the right to cast a majority of the votes that may be cast at a general meeting of the shareholders of a corporation;

 

		.2	the right to elect or appoint, directly or indirectly, a majority of the directors of a corporation;

 

		.3	to hold more than 50% of the interests of a partnership other than a limited partnership; and

 

		.4	to be the general partner of a limited partnership.

 

		1.1.12	“Effective Date” shall have the meaning
set out in Section 2.3.4

 

		1.1.13	“Financing” means capital secured
for, and accepted by, the Company including without limitation through any purchase, transfer or other disposition of any debt,
equity or other securities of the Company.

 

		1.1.14	“Inventions” means any and all
                                                                   discoveries, developments, enhancements, improvements, concepts, formulas, processes, ideas, writings, whether or not reduced to practice, industrial and other designs,
patents, patent applications, provisional patent applications, continuations, continuations-in-part, substitutions, divisionals,
reissues, renewals, re-examinations, extensions, supplementary protection certificates or the like, trade secrets or utility models,
copyrights and other forms of intellectual property including all applications, registrations and related foreign applications
filed and registrations granted thereon.

 

    4 

     

    

 

		1.1.15	“Key Contacts” means the actual and
potential: licensors, licensees, sublicensees, collaborators, partners, investors, shareholders, acquirers, lenders or merger candidates,
suppliers and customers of the Company or any Affiliate of the Company.

 

		1.1.16	“Notice Period” shall have the meaning
set out in Section 6.1 (Termination by Employee)

 

		1.1.17	“Objectives” shall have the meaning
set out in Section 3.3 (Annual Bonus)

 

		1.1.18	“Option Agreement” shall have the
meaning set out in Section 3.4 (Stock Options).

 

		1.1.19	“Person” means any individual, partnership,
joint venture, syndicate, sole proprietorship, company or corporation with or without share capital, trust, trustee, executor,
administrator, or other legal personal representatives, regulatory body or agency, government or governmental agency, authority
or entity howsoever designated or constituted.

 

		1.1.20	“Technical Information” means all
technical information of the Company or any Affiliate of the Company, including information regarding knowledge or data of an intellectual,
technical, scientific or industrial nature, including compositions of matter, techniques, specifications, standards, technical
data, uses of matter, practices, methods, computer data, scientific strategies and concepts, clinical and regulatory strategies
and concepts, test data, research data, analytical and quality control data, formulation data, manufacturing data, development
information, filings for the protection of intellectual property protection, drawings, specifications, designs, plans, proposals,
reports, formulas, compilations, research data and manuals.

 

		1.1.21	“Term of Employment” means the period
from the Effective Date until the date on which your employment with the Company ceases in accordance with Article 6.

 

		1.1.22	“Termination Date” shall have the
meaning set out in Section 6.7.

 

		1.1.23	“Work Product” means any and all
works of authorship, including

 

		.1	all Inventions and possible Inventions relating to the Company’s
Business resulting from any work performed by you for the Company that you may invent or co-invent during your involvement in any
capacity with the Company, except those Inventions invented by you entirely on your own time that do not relate to the Company’s
Business or do not derive from any equipment, supplies, facilities, Confidential Information or other information, gained, directly
or indirectly, by you from or through your involvement in any capacity with the Company; and

 

		.2	all Technical Information and Business Information resulting from any work performed by you for the Company; and includes all
analyses, compilations, studies, reports or other documents prepared by you based upon or including any such information, data
or knowledge of the Company or any Affiliate of the Company.

 

    5 

     

    

 

Article 2 Position, Duties and Service

 

	2.1	Position and Duties

 

You will be employed by and will serve the Company Chief Commercial
Officer, having the duties and functions customarily performed by, and having all responsibilities customary to, Chief Commercial
Officer, including those described in Exhibit 2.1.

 

You will report directly to the CEO of the Company. The rights
of the Company as provided in this Agreement may be exercised on behalf of the Company only by the CEO, Board, or by a committee
or person expressly designated for such purposes by the Board.

 

	2.2	Changes to Duties

 

Your duties and functions pertain to the Company or any Affiliate
of the Company and may be varied or added to from time to time by the CEO and the Board in its discretion.

 

	2.3	Service to the
Company

 

During the Term of Employment, you will:

 

		2.3.1	well and faithfully serve the Company, at all times act in the best interests of the Company,
and, to the extent necessary to discharge the responsibilities assigned to you hereunder, you will use your best efforts to perform
faithfully and efficiently such responsibilities;

 

		2.3.2	apply your skill and experience to the performance of your duties in such employment;

 

		2.3.3	comply with all policies and procedures from time to time formulated by the Company;

 

		2.3.4	devote all of your working time, attention and energies to the business and affairs of the
Company; and

 

		2.3.5	not, without the prior approval of the Company, carry on or engage in any other business or
occupation or become a director, officer, employee or agent of or hold any position or office with any other company, firm or person
other than the Company, except as disclosed in Exhibit 2.3.5 or as a volunteer for a non-profit organization, engaging in civic,
religious, educational or other community activities, or maintaining personal investments or a personal holding company, provided
that such activities do not materially interfere with
the performance of your duties under this Agreement. 

 

	2.4	Term

 

The terms and conditions of
this Agreement shall have effect as and from January 6, 2020 (the “Effective Date”)
and throughout the Term of Employment.

 

    6 

     

    

 

Article 3 Compensation Generally

 

	3.1	No Other Compensation
or Benefits

 

You will be compensated as set out in this Article. Unless otherwise
agreed by the parties in writing, you expressly acknowledge and agree that you will not be entitled by reason of your employment
by the Company or by reason of any termination of such employment, to any remuneration, compensation, severance, damages or benefits
other than as expressly set forth in this Agreement, the Option Agreement and as expressly required by applicable employment standards
legislation.

 

	3.2	Base Salary

 

During the Term of Employment,
the Company will pay you an annual base salary (the “Base Salary”):

 

		3.2.1	at the rate of $240,000 per annum,

 

payable on a bi-weekly basis (26 pay periods), subject to applicable
withholdings and deductions. The Base Salary will be reviewed on an annual basis, or as otherwise determined by the Company. Any
merit increases are subject to the approval and discretion of the Board. As a managerial employee of the Company, you are not entitled
to overtime pay.

 

	3.3	Annual Bonus

 

An
annual bonus will be in effect, and is based on you meeting established performance objectives and due 30 days after the
board has approved the corporate yearend financial statements. During the Term of Employment, you will be eligible for a
target cash bonus of up to 25% of your Base Salary under this Agreement if the Board (or the Company’s
Compensation Committee), in its sole discretion, determines that the Company has met its short-term and long-term business
performance objectives and that you have met your personal performance objectives (together, the “Objectives”),
which Objectives will be established on an annual basis by the CEO and Board (or the Company’s
Compensation Committee) in consultation with you. Payment of the performance bonus (less all applicable statutory deductions
by the Company) will be made to you once approved by the Board (or Company’s
Compensation Committee), and within 30 days after the board has approved the corporate yearend financial statements, provided
that, except as otherwise set out in this Agreement, at the time of such approval, you hold current active employment status
with the Company. You acknowledge that participation in any incentive or bonus plan during any one year confers no rights
upon you or any obligations on the Company to continue the plan or entitle you to participate in the plan in succeeding
years. Except only as expressly required by the applicable employment standards legislation, as amended, no incentives or
bonuses will be paid or are payable to you following the Termination Date and you waive any entitlement to damages in
lieu thereof whether pursuant or attributable to any common law notice period or otherwise.

 

    7 

     

    

 

	3.4	Founders Common
Shares

 

You will receive founders common shares equivalent to 300,000
of the initial share capital of the company.

 

	3.5	Stock Options

 

From time to time, subject to the terms and conditions of the
Option Agreement and at the approval of the Board of Directors, you may be entitled to receive an annual performance-based allocation
of stock options in the Company equivalent in shares to 20% of your salary, i.e. $240,000 X 20% = 48,000 shares

 

Except only as expressly required by applicable employment standards
legislation, as amended, or expressly required by the terms of this Agreement, as of the Termination Date, there shall be no further
awards of or vesting of stock options, restricted stock units, or other equity-based compensation, and any unvested stock options,
restricted stock units, or other equity-based compensation shall immediately be cancelled and terminate, and you waive any entitlement
to damages in lieu thereof whether pursuant or attributable to any common law notice period or otherwise.

 

	3.6	Stock Options in
the Event of a Change of Control

 

Subject to the terms and conditions of the Option Agreement,
in the event that as of the date of a Change of Control, you hold unvested stock options that had been granted to you under the
Option Agreement, such unvested stock options shall immediately vest and shall be exercisable in accordance with the terms and
conditions of the Option Agreement.

 

	3.7	Reimbursement for
Expenses

 

As of the Effective Date, the Company agrees to reimburse you
for reasonable travelling and other expenses incurred in the course of employment. For all such expenses, you will be required
to keep proper accounts and to furnish such statements and vouchers to the Company.

 

	3.8	Vacation

 

During the Term of Employment,
you will be entitled to 20 working days’ vacation, pro-rated for any partial year
of employment. The Company reserves the right to request that vacations be scheduled so as not to conflict with business needs.
While you must take at least your minimum statutory entitlement to vacation each year, any unused vacation balance remaining at
calendar year end in excess of minimum statutory vacation entitlements may be carried over into the subsequent calendar year to
a cumulative maximum not exceeding 40 working days of vacation. Subject to applicable employment standards legislation, any vacation
carried over in excess of 40 days will be forfeited.

 

    8 

     

    

 

 

3.9       Benefits

 

During
the Term of Employment, the Company will provide for group health, drugs, dental, vision and life insurance benefits through a
mutually agreeable arrangement as is made available to its executives from time to time. You hereby acknowledge that coverage
under any benefit plan, or alternate plan arrangement as agreed upon in effect from time to time is subject to availability and
other requirements of the applicable insurer and that the components of the benefits plan may be amended, modified or terminated
from time to time by the Company in its sole discretion, and that this may include terminating or changing carriers.

 

Article
4 Intellectual Property Rights

 

4.1       Obligation
of Confidentiality

 

You
understand and agree that in the course of your employment with the Company, both before and after the Effective Date, you have
obtained and will obtain knowledge of Confidential Information. You agree that unless the Company otherwise agrees in writing
or except as required by law or disclosed pursuant to a confidential disclosure agreement executed by the Company and the recipient:

 

		4.1.1	you
                                         will keep all Confidential Information learned or acquired by you, disclosed to you or
                                         developed by you, as a result of or in connection with or during the course of your employment
                                         by the Company, whether before or after the Effective Date, strictly confidential;

 

		4.1.2	all
                                         Confidential Information shall, as between you and the Company, be and remain the property
                                         of the Company; and

 

		4.1.3	you
                                         will not at any time, during or after your employment with the Company, disclose any
                                         Confidential Information to any Person other than the Company, or use any Confidential
                                         Information for the benefit of any Person other than the Company.

 

The
above obligations with respect to Confidential Information shall not apply to Confidential Information which has become available
to the general public through no fault of your own.

 

4.2       Disclosure
of Work Product

 

You
agree to promptly and fully inform the Company of all of your Work Product, whether or not patentable, throughout the course of
your involvement, in any capacity, with the Company or any Affiliate of the Company, whether or not developed before or after
your execution of this Agreement. On your ceasing to be employed by the Company, you will immediately deliver up to the Company
all of your Work Product. You further agree that all of your Work Product shall at all times be the Confidential Information of
the Company.

 

4.3       Assignment
of Rights

 

You
will assign, and do hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company’s
designee, your entire right, title and interest in and to all of your Work Product and all other rights and interests of a proprietary
nature in and associated with your Work Product, including all patents, copyrights, trademarks, and applications filed therefore
and other registrations granted thereon. To the extent that you retain or acquire legal title to any such rights and interests,
you hereby declare and confirm that such legal title is and will be held by you only as trustee and agent for the Company. You
agree that the Company’s rights hereunder shall attach to all of your Work Product,
notwithstanding that it may be perfected or reduced to specific form after you have terminated your relationship with the Company.
You further agree that the Company’s rights hereunder shall extend to every country
of the world.

 

    9 

     

    

 

4.4       Moral
Rights

 

You
agree to hereby waive in whole all moral rights and agree never to assert any moral rights which you may have in your Work Product,
including, without limitation, the right to the integrity of such Work Product, the right to be associated with the Work Product,
the right to restrain or claim damages for any distortion, mutilation or other modification or enhancement of the Work Product
and the right to restrain, the use or reproduction of the Work Product in any context and in connection with any product, service,
cause or institution and you further confirm that the Company may use or alter any such Work Product as the Company sees fit in
its absolute discretion.

 

4.5       Goodwill

 

You
hereby agree that all goodwill you have established or may establish with Key Contacts relating to the business or affairs of
the Company or any Affiliate of the Company, both before and after the Effective Date, shall, as between you and the Company,
be and remain the property of the Company exclusively, for the Company to use, alter, vary, adapt and exploit as the Company shall
determine in its discretion.

 

4.6       Assistance

 

You
hereby agree to assist the Company, at the Company’s
request and expense, both during your Term of Employment and at all times after termination of your Term of Employment for any
reason whatsoever, in:

 

		4.6.1	making
                                         patent applications for your Work Product, including instructions to lawyers and/or patent
                                         agents as to the characteristics of your Work Product in sufficient detail to enable
                                         the preparation of a suitable patent specification, to execute all formal documentation
                                         incidental to an application for letters patent and to execute assignment documents in
                                         favor of the Company for such applications;

 

		4.6.2	making
                                         applications for all other forms of intellectual property registration relating to your
                                         Work Product;

 

		4.6.3	prosecuting
                                         and maintaining the patent applications and other intellectual property relating to your
                                         Work Product; and

 

		4.6.4	registering,
                                         maintaining and enforcing the patents and other intellectual property registrations relating
                                         to your Work Product.

 

    10 

     

    

 

4.7       Assistance
with Proceedings

 

You
further agree to lend such assistance as you can, at the Company’s
request and expense, in connection with any enforcement of the Company’s intellectual
property rights or defense to an allegation of infringement of another Person’s intellectual
property rights, invalidity proceedings respecting, opposition to, or intervention regarding any applications for letters patent,
copyright or trademark or other proceedings relating to intellectual property or applications for registration thereof.

 

Article
5 Conflicts and Restrictive Covenant

 

5.1       Disclosure
of Conflicts of Interest

 

During
your employment with the Company, you will promptly, fully and frankly disclose to the Company in writing:

 

		5.1.1	the
                                         nature and extent of any interest you have or may have, directly or indirectly, in any
                                         contract or transaction or proposed contract or transaction of or with the Company or
                                         any Affiliate of the Company or any Key Contact;

 

		5.1.2	every
                                         office you may hold or acquire, and every property you may possess or acquire, whereby
                                         directly or indirectly, a duty or interest might be created in conflict with the interests
                                         of the Company or any Affiliate of the Company, or your duties and obligations under
                                         this Agreement; and

 

		5.1.3	the
                                         nature and extent of any conflict referred to in Sections 5.1.1 and 5.1.2.

 

5.2       Avoidance
of Conflicts of Interest

 

You
acknowledge that it is the policy of the Company that all interests and conflicts of the sort described in Section 5.1 (Disclosure
of Conflicts of Interest) be avoided, and you agree to comply with all policies and directives of the Company from time to time
regulating, restricting or prohibiting circumstances giving rise to interests or conflicts of the sort described in Section 5.1.
During your employment with the Company, you shall not enter into any agreement, arrangement or understanding with any other Person
that would in any way conflict or interfere with this Agreement or your duties or obligations under this Agreement or that would
otherwise prevent you from performing your obligations hereunder, and you represent and warrant that you have not prior to the
Effective Date entered into any such agreement, arrangement or understanding.

 

    11 

     

    

 

5.3       Restrictive
Covenant

 

During
the Term of Employment and for a period of 6 months thereafter for Sections 5.3.1 and 5.3.2, and a period of 24 months thereafter
for Section 5.3.3, regardless of the reason for such termination, you will not, either alone or in partnership or in conjunction
with any Person, whether as principal, agent, employee, director, officer, shareholder, consultant or in any capacity or manner
whatsoever, whether directly or indirectly:

 

		5.3.1	carry
                                         on or be engaged in, or advise, or give financial assistance to, any business, enterprise
                                         or undertaking within Canada that:

 

		.1    	is
                                         involved in the business or in the sale, distribution, development or supply of any product
                                         or service that is competitive with the Business or any product or service of the Business;
                                         or

 

		.2    	competes
                                         with the Company with respect to any aspect of the Business; provided, however, that
                                         the foregoing will not prohibit you from acquiring, solely as an investment and through
                                         market purchases, securities of any such enterprise or undertaking which are publicly
                                         traded, so long as you are not part of any control group of such entity and such securities,
                                         which if converted, do not constitute more than 5% of the outstanding voting power of
                                         that entity;

 

		5.3.2	agree
                                         to be employed by, or agree to provide services within Canada to any Person that was
                                         a Key Contact (but in any case, with whom you have had business contact during the two
                                         years prior to the termination of the Term of Employment, or with whom you have had business
                                         contact in the course of your employment with the Company if less than 24 months) for
                                         any business purpose that is competitive with the Business; or

 

		5.3.3	solicit,
                                         divert, entice or take away from the Company or any Affiliate of the Company or attempt
                                         to do so or solicit for the purpose of doing so, any business of the Company or any Affiliate
                                         of the Company, or any Person that was an employee or contractor of the Company or any
                                         Affiliate of the Company (but in any case, with whom you have had business contact during
                                         the two years prior to the termination of the Term of Employment, or with whom you have
                                         had business contact in the course of your employment with the Company if less than two
                                         years) to terminate, discontinue or alter to the detriment of the Company, his, her or
                                         its employment relationship with the Company or its Affiliates.

 

5.4       Provisions
Reasonable

 

You
hereby acknowledge and agree that:

 

		5.4.1	during
                                         the course of your employment by the Company, you will acquire knowledge of, and you
                                         will come into contact with, initiate and established relationships with Key Contacts,
                                         and that in some circumstances you may be the senior or sole representative of the Company
                                         or any Affiliate of the Company dealing with such Persons; and

 

		5.4.2	in
                                         light of the foregoing, the provisions of Section 5.3 (Restrictive Covenant) are reasonable
                                         and necessary for the proper protection of the business, property and goodwill of the
                                         Company and the Business and any Affiliate of the Company.

 

5.5       Right
to Use Employee’s Name and Likeness

 

During
the Term of Employment, you hereby grant to the Company the right to use your name, likeness and/or biography in connection with
services performed by you under this Agreement and in connection with the advertising or exploitation of any project with respect
to which you perform services for the Company.

 

    12 

     

    

 

Article
6 Termination

 

6.1       Termination
by Employee

 

You
may resign from your position at any time, but only by giving the Company at least 30 days prior written notice of the effective
date of your resignation (the “Notice
Period”). On the giving of any such notice, the Company may accelerate your resignation,
in lieu of the Notice Period or any part thereof, by notice in writing to you and payment to you of any compensation and continuation
of benefits due to you for the balance of the 30-day Notice Period pursuant to this Agreement, less applicable statutory deductions.

 

6.2       Termination
by Company Without Cause

 

The
Company may terminate your employment at any time without Cause (as defined below) in accordance with the terms set out in this
Agreement and by giving you written notification of termination. In the event that your employment is so terminated, you will
have the common law duty to mitigate your damages.

 

6.3       Consequences
of Termination Without Cause Unrelated to a Change of Control

 

Subject
to Section 6.4, on the giving of any notice referred to in Section 6.2, the Company shall provide you with the greater of either
(i) 3 months’ Base
Salary and bonus (3.3), in addition to 1 month for every year of service (or part thereof) to the company upon and effective at
3 years of employment,, or (ii) the minimum notice or pay in lieu of notice and severance pay, if applicable, that is expressly
required by applicable employment standards legislation. In the case of either Section 6.3(i) or (ii), your participation in Company
benefits plans will be continued for the minimum period expressly required by applicable employment standards legislation. Other
than as set out in this Section and Section 6.7, you will not be entitled to any additional notice, pay in lieu of notice, severance
or other payments whether pursuant to the common law or otherwise upon termination of your employment without Cause unrelated
to a Change of Control pursuant to this Section 6.3.

 

6.4       Consequences
of Termination Without Cause After a Change of Control

 

On
the giving by the Company to you of the written notice referred to in Section 6.2: (i) at the same time as, or within the twelve
(12) month period following, the consummation of a Change of Control, or (ii) within the thirty (30) day period prior to the date
of the consummation of a Change of Control where such Change of Control was under consideration by the Board at the time of your
termination, then the following terms apply in substitution of the compensation and benefits referred to in Section 6.3 above:

 

		6.4.1	the
                                         Company shall provide you with the greater of either (i) 6 months’
                                         Base Salary and bonus (3.3), in addition to 1 month for
                                         every year of service (or part thereof) to the company, upon and effective at 3 years
                                         of employment., or (ii) the minimum notice or pay in lieu of notice and severance pay,
                                         if applicable, that is expressly required by applicable employment standards legislation,
                                         plus in the case of either Section 6.4.l(i) or (ii), your participation in Company benefits
                                         plans will be continued for the minimum period expressly required by applicable employment
                                         standards legislation; and

 

		6.4.2	as
                                         set out in and subject to the terms of Section 3.5 above, as of the date of the consummation
                                         of the Change of Control, any unvested stock options granted to you under the Option
                                         Agreement will vest and be exercisable in accordance with the terms and conditions of
                                         this Option Agreement.

 

Other
than as set out in this Section and Section 6.7 below, you will not be entitled to any additional vesting, notice, pay in lieu
of notice, severance or other payments whether pursuant to the common law or otherwise upon termination of your employment without
Cause after a Change of Control pursuant to this Section 6.4.

 

    13 

     

    

 

6.5       Termination
in the Event of Death

 

Your
employment shall terminate immediately upon your death and the Company shall pay your estate any amounts which may be due and
remaining unpaid at the time of the termination of employment, in accordance with applicable employment standards legislation.

 

6.6       Termination
by Company for Cause

 

Notwithstanding
any other provision in this Agreement, the Company may at any time summarily terminate your employment, without any obligation
to provide notice of pay in lieu of notice, for “Cause”,
in which case you will only be entitled to receive such compensation and benefits as are expressly required by applicable employment
standards legislation. In this Agreement, “Cause” means
any of the following:

 

		6.6.1	commission
                                         of theft, embezzlement, fraud, obtaining funds or property under false pretenses or similar
                                         acts of misconduct with respect to the property of the Company, any Affiliate of the
                                         Company, the Key Contacts, or their respective directors, officers, employees or contractors;

 

oral
or written representations made by you to the Company or any Affiliate of the Company with the intent to deceive or mislead; commission
of an act of malfeasance, dishonesty or breach of trust against the Company, any Affiliate of the Company, the Key Contacts, or
their respective directors, officers, employees or contractors, including a breach by you of any of your covenants or obligations
under Section 5.1 (Disclosure of Conflicts of Interest), Section 5.2 (Avoidance of Conflicts of Interest) or Section 5.3 (Restrictive
Covenant);

 

		6.6.2	the
                                         entering of a guilty plea by you or your conviction for a serious criminal offence which
                                         impacts adversely on the Company or any Affiliate of the Company;

 

		6.6.3	repeated
                                         and continued failure to fulfill your duties or obligations of employment or your breach
                                         of any material obligations and covenants under this Agreement. Termination for such
                                         “Cause”
                                         shall only occur if you have been given written notice
                                         of such failure to fulfill your duties or obligations and you have been given an opportunity
                                         to correct such behavior;

 

		6.6.4	the
                                         termination of your employment with POINT Biopharma Corp. other than a termination pursuant
                                         to section 6.2; or

 

		6.6.5	any
                                         other misconduct or omission that amounts to just cause for summary dismissal at common
                                         law. In the event the Company dismisses you for cause pursuant to this Section 6.6 and,
                                         subsequently, a court or arbitrator rules that the Company did not have cause, you hereby
                                         agree that you will only be entitled to damages in an amount equal to the compensation
                                         that would have been due to you had the Company terminated your employment pursuant to
                                         Section 6.3 (Consequences of Termination Without Cause), less any amounts earned by you
                                         in mitigation.

 

    14 

     

    

 

6.7       Termination
Date and Full Satisfaction

 

“Termination
Date” means the earlier of: (i) the date on which you are notified in writing by
the Company of the termination of your employment for any reason, and (ii) the date on which you notify the Company of your resignation
from employment for any reason, but in any case, without regard to any payment or notice period to which you might then be entitled.

 

It
is agreed that as a result of the termination of your employment, for any reason, you shall not be entitled to any notice, fee,
salary, severance or other payments, benefits or damages in excess of what is specified or provided for in Section 6.1 (Termination
by Employee), Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences
of Termination Without Cause After a Change of Control) and Section 6.6 (Termination by Company for Cause), whichever is applicable,
except that you shall remain receive all salary and other amounts, if any, which are then due and owed to you as of the Termination
Date, in addition to any accrued but unpaid vacation pay and any other minimum entitlements expressly required to be provided
to you by applicable employment standards legislation. Payment of any amounts pursuant to Section 6.1 (Termination by Employee),
Section 6.3 (Consequences of Termination Without Cause Unrelated to a Change of Control), Section 6.4 (Consequences of Termination
Without Cause After a Change of Control), and Section 6.6 (Termination by Company for Cause) shall be subject to the withholding
of all applicable statutory deductions by the Company. You will be required to execute a standard release of claims document in
a form satisfactory to the Company in order to receive any payments in excess of those required by applicable employment standards
legislation.

 

    15 

     

    

 

Article
7 General

 

7.1       Agreement
Confidential

 

Both
parties shall keep the terms and conditions of this Agreement confidential except as may be required to enforce any provision
of this Agreement or as may otherwise be required by any law, regulation or other regulatory or securities requirement.

 

7.2       Binding
Effect

 

This
Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns. Your rights and obligations
contained in this Agreement are personal and such rights, benefits and obligations shall not be voluntarily or involuntarily assigned,
alienated or transferred, whether by operation of law or otherwise, without the prior written consent of the Company. This Agreement
shall otherwise be binding upon and inure to the benefit of your personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees, legatees and permitted assigns.

 

7.3       Counterparts

 

This
Agreement may be executed in several counterparts (including by fax or electronic transmission), each of which when so executed
shall be deemed to be an original and shall have the same force and effect as an original but such counterparts together shall
constitute but one and the same instrument.

 

7.4       Entire
Agreement

 

The
terms and conditions of this Agreement are in addition to and not in substitution for the obligations, duties and responsibilities
imposed by law on employees of corporations generally, and you agree to comply with such obligations, duties and responsibilities.
Except as otherwise provided in this Agreement, this Agreement constitutes the entire agreement between you and the Company and
supersedes all prior negotiations, proposals and agreements, whether oral or written, with respect to the subject matter hereof,
and may only be varied by further written agreement signed by you and the Company. You further acknowledge and agree that you
have not relied on any representation made by the Company, or any of its employees or agents, except as specifically set out in
this Agreement.

 

7.5       Further
Assurances

 

Each
of the parties hereto will, on demand by the other party hereto, execute and deliver all such further documents and instruments
and do all such further acts and things as the party may either before or after the execution and delivery of this Agreement reasonably
request to evidence, carry out and give full effect to the terms, conditions, intent and meaning of this Agreement.

 

7.6       Governing
Law

 

This
Agreement shall be construed and enforced in accordance with and be governed by and interpreted in accordance with the laws of
the Province of Ontario and the law of Canada applicable therein, without regard to the principles of conflicts of law. The courts
of Ontario (and the Supreme Court of Canada, if necessary) shall have exclusive jurisdiction to hear and determine all disputes
arising hereunder, and each of the parties hereto irrevocably attorns to the jurisdiction of said courts.

 

    16 

     

    

 

7.7       Independent
Legal Advice

 

You
acknowledge and agree that the Company has given you the opportunity to seek, and has recommended that you obtain, independent
legal advice with respect to the subject matter of this Agreement and, further, you hereby represent and warrant to the Company
that you have either sought independent legal advice or have waived your right to obtain such advice.

 

7.8       Injunctive
Relief

 

You
acknowledge and agree that any breach or threatened breach of any of the provisions of, Section 5.1 (Disclosure of Conflicts of
Interest), Section 5.2 (Avoidance of Conflicts of Interest), or Section 5.3 (Restrictive Covenant) could cause irreparable damage
to the Company, that such harm could not be adequately compensated by the Company’s
recovery of monetary damages, and that in the event of a breach or threatened breach thereof, the Company shall have, in addition
to any and all remedies at law or in equity, the right to seek an injunction, specific performance or other equitable relief as
well as any equitable accounting of all your profits or benefits arising out of any such breach. It is further acknowledged and
agreed that the remedies of the Company specified in this Section 7.8 are in addition to and not in substitution for any rights
or remedies of the Company at law or in equity and that all such rights and remedies are cumulative and not alternative and that
the Company may have recourse to any one or more of its available rights or remedies as it shall see fit.

 

7.9       Non-Disparagement

 

You
shall not, directly or indirectly, make any disparaging comments or criticisms (whether of a professional or personal nature)
to any Person regarding the Company, any Affiliate of the Company, the Key Contacts, or their respective directors, officers,
employees or contractors (or the terms of any agreement or arrangement of the Company) or regarding your relationship with the
Company or any termination of such relationship which, in each case, are reasonably expected to result in material damage to the
business or reputation of the Company, any Affiliate of the Company, a Key Contact, or any of their respective directors, officers,
employees or contractors.

 

7.10     Notice

 

Any
notice or other communication required or contemplated to be given hereunder must be in writing and shall be deemed effective
when personally delivered or on the day following the sending when sent by facsimile transmission, addressed to the appropriate
party as set forth below:

 

If
to the Employee:

 

Michael
Gottlieb

579
Bedford Park Avenue

Toronto,
ON M5M 1M5

 

If
to the Company:

 

POINT
Biopharma Corp.

22
St. Clair Ave. East, Suite 1201,

Toronto,
ON M4T 2S3

 

Attention:
CEO, Joe McCann

 

With
a copy to (which shall not constitute notice):

 

Goodmans
LLP

Bay
Adelaide Centre - West Tower

333
Bay Street, Suite 3400

Toronto,
ON

M5H
2S7

 

    17 

     

    

 

7.11     Publicity

 

You
shall not, without the prior written consent of the Company, make or give any public announcements, press releases or statements
to the public or the press regarding your Work Product or any Confidential Information.

 

7.12     Severability

 

If
any provision of this Agreement is determined to be void, illegal or unenforceable, such provision will be construed to be separate
and severable from this Agreement and will not impair the validity, legality or enforceability of any other provision of this
Agreement and the remainder of this Agreement will continue to be binding on the parties hereto as if such provision had been
deleted.

 

7.13     Surviving
Obligations

 

Upon
termination of this Agreement for any reason, any obligations which by their terms or nature, must extend beyond the date of termination
to be effective shall survive termination of this Agreement. Without limiting the foregoing, your obligations under Section 5.3
(Restrictive Covenant), Section 5.4 (Provisions Reasonable), Article 6 (Termination) and Article 7 (General) shall survive and
remain in full force and effect following the termination of this Agreement.

 

7.14     Waiver

 

Any
waiver of any breach or default under this Agreement shall only be effective if made in writing, signed by the party against whom
the waiver is sought to be enforced, and no waiver shall be implied by any other act or conduct or by any indulgence, delay or
omission. Any waiver shall only apply to the specific matter waived and only in the specific instance in which it is waived.

 

    18 

     

    

 

 

7.15     Acceptance

 

If
the foregoing terms and conditions are, are acceptable to you, please indicate your acceptance of and agreement to the terms and
conditions of this agreement by signing below on this letter and on the enclosed copy of this letter in the space provided and
by returning the enclosed copy so executed to us. Your execution and delivery to the Company of the enclosed copy of this letter
will create a binding agreement between us.

 

Yours
truly,

POINT
Biopharma Corp.

 

	Per:	 /s/ Joe McCann	 

Authorized
Signatory

 

Joe
McCann, Chief Executive Officer

 

Acknowledged
and Agreed:

 

I
acknowledge that I have had sufficient time to thoroughly review this agreement and obtain the advice that I deem appropriate
regarding its terms and conditions. I have read, understand and voluntarily accept employment with POINT Biopharma Corp. on the
terms and conditions set out above.

 

	April
    23, 2020	/s/
    Michael Gottlieb 
	Date	Michael
    Gottlieb

 

    19 

     

    

 

 

Exhibit 1.1.5: Description of the Business

 

The Company is a clinical stage pharmaceutical company focused
on the development and commercialization of radiotherapeutics and theranostic products. The company will compete in all medical
therapeutic categories.

 

    20 

     

    

 

Exhibit 2.1: Description of Duties –
Chief Commercial Officer

 

The Chief Commercial Officer provides both operational
and programmatic support to the organization. The Chief Commercial Officer oversees all commercial initiatives for the organization.
The Chief Commercial Officer reports directly to the Chief Executive Officer (CEO) and directly assists the executive make
strategic decision to achieve the companies stated business and financial objectives.

 

ESSENTIAL DUTIES AND RESPONSIBILITIES

 

With the CEO

 

		·	Provide leadership in the development of continuous
performance improvement business processes and systems. (in fact create them)

 

		·	Lead the measurement and effectiveness of all internal
and external processes, including KPIs. Use data to make decisions and drive performance.

 

		·	Provide timely, accurate and complete reports on
the operating condition of the company to the Board of Directors, CEO and executive leadership.

 

		·	Support the development, communication and implementation
of effective growth strategies, processes and new programs and/or service lines within product procurement and distribution.

 

		·	Collaborate with the CEO and executive leadership
team to develop and implement plans for operational infrastructure of systems, processes, and personnel designed to accommodate
strategic objectives of the organization.

 

		·	Select and maintain qualified personnel in all
positions who report directly to him/her/them.

 

		·	As a HR steward, Assure staff performance results
by coaching, counseling, mentoring, planning, monitoring and evaluating job performance.

 

In collaboration with the CFO

 

		·	Participate in the development and preparation
of short-term and long-range plans and budgets based upon broad organization goals and objectives

 

		·	Negotiate and manage high level vendor contracts
as needed.

 

		·	Develop and establish operating policies consistent
with the CEO/CFO broad finance policies and objectives and ensure their adequate execution

 

For: Corporate Operation:

 

		·	Foster a success-oriented and accountable environment
within the organization.

 

		·	Represent the organization at community functions
and increase visibility of the organization within the communities it serves.

 

		·	Ensure that all activities and operations are performed
in compliance with Health regulators, local, provincial, and federal regulations and laws governing business operations

 

		·	Maintain and foster a quality culture focused on
cGMP compliance and ISO standards.

 

		·	Drives operational excellence through process improvements,
utilization of automation solutions and performance metrics.

 

		·	Will evaluate 3PL growth projections to ensure
network capacity needs are met.

 

		·	Ensures the security and accountability of materials
and goods with inventory control.

 

		·	Monitors and analyzes strategic growth opportunities
with acquisitions and strategic partnerships.

 

    21 

     

    

 

Exhibit 2.3.5: Permitted External Roles

 

1. To be determined.

2. Blank as of October
18, 2019

3. To be amended per
employee activity

 

    22 

     

    

 

	OFFICE 833.544.2637

FAX 647.243.8490

22 St. Clair Avenue East, Suite 1201

Toronto, Ontario, M4T 2S3, Canada

4850 W 78th St Indianapolis, Indiana, 46268, USA	 

 

March 8, 2021

 

Michael Gottlieb

579 Bedford Park Ave

Toronto, ON M5M1M5

 

Dear Michael

 

In connection with the Employment
Agreement (the “Employment Agreement”)
dated April 23, 2020 between you and Point Biopharma Corp. (the “Company”),
you agree that the provisions set out in this letter agreement amend the Employment Agreement.

 

Signing Bonus

 

You have agreed with the Company to accept a signing bonus of
$2,000.00, which will be paid to you by the Company in consideration for your agreement to the amendments to the Employment Agreement
set out in this letter agreement as evidenced by your signed Acceptance below.

 

Definitions

 

The definitions of “Affiliate”
and “Key Contacts” in
Sections 1.1.2 and 1.1.15 of the Employment Agreement are deleted and replaced with the following:

 

1.1.2 “Affiliate”
means with respect to a Person, any Person that, directly or indirectly, Controls, is Controlled
by, or is under common Control with such Person, including, without limitation, any partner, officer, director, or member of such
Person and any venture capital fund now or hereafter existing that is Controlled by or under common Control with one or more general
partners or shares the same management company or investment manager with such Person, and including any parent or subsidiary company
of such Person and “Protected Affiliate” means
an Affiliate with whom you have been actively engaged in business contact in the course of your employment with the Company in
the 18 months prior to the Termination Date (as that term is defined in subsection 5.3.3.1 of this Agreement) or in respect of
whom you acquired confidential or proprietary information during the course of your employment with the Company that the Company
has a reasonable and legitimate business interest in protecting from use or disclosure by its former employees

 

1.1.15 “Key
Contacts” means the actual and potential licensors, licensees, sublicensees, collaborators,
partners, investors, shareholders, acquirers, lenders or merger candidates, suppliers and customers of the Company or any Protected
Affiliate with whom you have been actively engaged in business contact or actively engaged in researching, developing or preparing
a business pitch or proposal in the course of your employment with the Company in the 18 months prior to the Termination Date,
or in respect of whom you acquired confidential or proprietary information during the course of your employment with the Company
that the Company has a reasonable and legitimate business interest in protecting from use or disclosure by its former employees.

 

Restrictive Covenant

 

Sections 5.3 and 5.4 of the Employment Agreement are deleted
and replaced with the following:

 

     

     

    

 

	OFFICE 833.544.2637

FAX 647.243.8490

22 St. Clair Avenue East, Suite 1201

Toronto, Ontario, M4T 2S3, Canada

4850 W 78th St Indianapolis, Indiana, 46268, USA	 

 

5.3           Restrictive
Covenants

 

During the Term of Employment and for
a period of 6 months thereafter for Sections 5.3.1 and 5.3.2, and a period of 18 months thereafter for Section 5.3.3,
regardless of the reason for such termination, you will not, either alone or in partnership or in conjunction with any
Person, whether as principal, agent, employee, director, officer, shareholder, consultant or in any capacity or manner
whatsoever, whether directly or indirectly:

 

 5.3.1       carry on or be engaged in, or advise, or give financial assistance to, any business, enterprise or undertaking within Canada and the United States that:

 

.1            is involved
in the business or in the sale, distribution, development or supply of any product or service that is the same as or substantially
similar to the products or services offered by the Company as at the date of the termination of your employment (the “Termination
Date”); or

 

.2            competes in a substantial or material way with
the Company with respect to any aspect of the Business as at the Termination Date; provided, however, that the foregoing will not
prohibit you from acquiring, solely as an investment and through market purchases, securities of any such enterprise or undertaking
which are publicly traded, so long as you are not part of any control group of such entity and such securities, which if converted,
do not constitute more than 5% of the outstanding voting power of that entity;

 

5.3.2       agree
to be employed by any Person that was a Key Contact as at the Termination Date for any business purpose that is competitive with
the Business in any substantial or material way; or make use of any list or proprietary information of or relating to a Key Contact
for the purpose of competing with the Company; or be involved in the sale to, solicitation of or servicing of any Key Contact where
such sale, solicitation or servicing is with respect to services or products which are the same or substantially similar to or
which compete with products or services sold or provided by the Company as at the Termination Date; or otherwise attempt to interfere
with or damage the Company’s business relationship with any Key Contact; or

 

5.3.3       solicit,
divert, entice, persu or take away from the Company or any Protected Affiliate the Company has a reasonable need to protect against
(a “Protected Affiliate”), or attempt
to do so or solicit for the purpose of doing so, any business of the Company or any Protected Affiliate, or any Person that was
an employee or contractor of the Company or any Protected Affiliate (but in any case, with whom you have had business contact in
the course of your employment with the Company during the 18 months prior to the Termination Date) to terminate, discontinue or
alter to the detriment of the Company, his, her or its employment or engagement relationship with the Company or its Protected
Affiliates or otherwise attempt to interfere with or damage the Company’s or a Protected
Affiliate’s relationship with any such person.

 

5.4           Provisions Reasonable

 

You hereby acknowledge and agree that:

 

5.4.1       the
Company has a material interest in preserving the relationships it has developed with its Key Contacts against impairment by competitive
activities of a former employee;

 

5.4.2       during
the course of your employment by the Company, you will acquire knowledge of, and you will come into contact with, initiate and
establish relationships with Key Contacts, and that in some circumstances you may be the senior or sole representative of the Company
or any Protected dealing with such Key Contacts; and

 

5.4.3       in
light of the foregoing, the provisions of Section 5.3 (Restrictive Covenant) are reasonable and necessary for the proper protection
of the business, property and goodwill of the Company and the Business and any Protected Affiliate and you further agree that these
restrictions and your agreement to them are of major importance to the Company, which would not employ or continue to employ you
if you did not agree to them.

 

     

     

    

 

 

	OFFICE 833.544.2637

FAX 647.243.8490

22 St. Clair Avenue East, Suite 1201

Toronto, Ontario, M4T 2S3, Canada

4850 W 78th St Indianapolis, Indiana, 46268, USA	 

 

Non-Disparagement

 

Section 7.9 of the Employment Agreement is deleted and replaced
with the following:

 

You shall not, directly or indirectly, make any disparaging
comments or criticisms (whether of a professional or personal nature and including any comments, statements or postings via any
social media website or application, including but not limited to Facebook, Twitter, LinkedIn, Flickr, YouTube, Picase, Snapchat,
Instagram, TikTok or Clubhouse) to any Person regarding the Company, any Affiliate of the Company, the Key Contacts, or their respective
directors, officers, employees or contractors (or the terms of any agreement or arrangement of the Company) or regarding your relationship
with the Company or any termination of such relationship which, in each case, are reasonably expected to result in material
damage to the business or reputation of the Company, any Affiliate of the Company, a Key Contact, or any of their respective directors,
officers, employees or contractors.

 

No Other Amendments

 

The parties acknowledge and agree that, except as specifically
amended above in this letter agreement, the Employment Agreement (including all definitions therein) remains in full force and
effect, unamended. All capitalized terms in this letter agreement which are not otherwise defined shall have the same meaning as
in the Employment Agreement.

 

	/s/ Joe McCann	 
	 	 
	For and on behalf of Point Biopharma Corp.

 

Acceptance

 

I have read and understand the terms and conditions of employment
set out in the Employment Agreement , as amended by this letter agreement and I agree to and accept them freely and voluntarily.
I confirm that I have had the opportunity to obtain advice regarding its contents, including from counsel of my choice. I understand
that, in the event of the termination of my employment (including without just cause), my entitlements will be limited to those
specified in this agreement.

 

Signed in Toronto, Ontario on March                 ,
2021.

 

	/s/ Donna Husack	 	/s/ Michael Gottlieb
	Witness Signature	 	Michael Gottlieb
	Name:  	Donna HusackExhibit
10.11

 

CONSULTING AGREEMENT

 

This
Consulting Agreement (this “Agreement”)
is entered into as of the February 22, 2021 (“Effective
Date”) and ending December 31, 2021 (“End
Date”) by and between POINT Biopharma Inc., a corporation duly incorporated under the laws of Delaware (“POINT”
or the “Company”), and
between Dr Neil Fleshner, 1510789 Ontario Inc. with a registered office at 610 University Ave. Suite 3-130 Toronto, Ontario (“Consultant”).
POINT and Consultant are hereinafter collectively referred to as the “Parties”
or singularly as the “Party.”
In consideration of the mutual covenants contained herein, the Parties agree to the following terms and conditions:

 

POINT
wishes to engage Consultant to perform certain consulting services (hereinafter referred to as the “Consulting
Services”), and Consultant wishes to accept such engagement in accordance with the terms and conditions of this
Agreement.

 

		1.	Consulting Services.

 

1.1.        Consultant hereby agrees to perform any and all such Consulting Services as further detailed in Schedule A attached hereto
and incorporated herein.

 

1.2.        As requested by POINT, Consultant shall provide to POINT oral or written reports and copies of any and all information related
to the Consulting Services, in a format that is acceptable to POINT. All reports and all data and information generated by the
Consulting Services hereunder are considered “Work
Product” under this Agreement. Consultant shall keep and maintain complete and accurate records that fully and
properly reflect all work done and results achieved in the performance of the Consulting Services. All such records shall be created
and kept in sufficient detail and in good scientific manner, and they shall be maintained by Consultant for such time as required
by applicable laws, rules and regulations.

 

1.3.        During the Term (as defined in Section 7), the performance of the Consulting Services by Consultant does not and will not
conflict with or result in breach of any term, condition, obligation or restriction of any other agreement of Consultant with any
third party. Furthermore, Consultant agrees that any Work Product will not contain any intellectual property, proprietary information,
content, software or other materials of any third party.

 

1.4.        This Agreement requires the personal services of Consultant and/or its employees or associates. Consultant may not subcontract
any obligations to third parties under this Agreement without POINT’s prior written consent. In the event that the personal services
of Consultant and/or its employees or associates are no longer available, POINT may immediately terminate this Agreement without
any further liability or obligation to Consultant.

 

		2.	Confidentiality.

 

2.1.        All information provided to Consultant by or on behalf of POINT or its affiliates, or otherwise acquired, including but not limited
to all proprietary and/or confidential information or facts of POINT or of any third party with which POINT deals (including customers
and suppliers of POINT), information relating to their respective business operations, equipment, products, services or intellectual
property, that the Consultant acquires in the course of providing the Consulting Services, whether or not such information: (i)
is reduced to writing; (ii) was created or originated by the Consultant;
or (iii) is designated or marked as “confidential”, “proprietary” or by some other designation or marking (collectively
“Confidential Information”)
is confidential and proprietary to POINT.

    Page 1 of 10

     

    

2.2.         Confidential Information is the sole and exclusive property of POINT. Consultant hereby assigns to POINT any and all rights,
title and interest Consultant may have or acquire in the Confidential Information or in any document or materials of POINT. For
the purposes of this Agreement, all Work Product and Inventions (as defined in Section 3 below) are considered Confidential Information
of POINT.

 

2.3.         The Consultant understands and acknowledges that Consultant’s engagement creates a relationship of confidence and trust
between POINT and the Consultant with respect to the Confidential Information. Consultant shall maintain the Confidential Information
in strict secrecy and confidence and shall not disclose any of the Confidential Information to any third party nor use it for any
purpose except to perform the Consulting Services. Consultant shall only make copies of the Confidential Information to the limited
extent reasonably required to provide the Consulting Services. Consultant shall not, without the prior written consent of POINT,
disclose to any person or entity any of the terms or conditions of this Agreement.

 

2.4.         Consultant represents and warrants to POINT that Consultant’s performance of all of its obligations set forth in this Agreement
and as a consultant of POINT does not and shall not breach any agreement to keep in confidence any information, knowledge or data
which is confidential or proprietary to a third party and which has been acquired by Consultant in confidence or in trust prior
to Consultant’s engagement by POINT, or violate the terms of any covenant not to compete between Consultant and any other person
or entity. Consultant shall not disclose to POINT or induce POINT to use any confidential or proprietary information or material
belonging to any previous employers of Consultant or any other person or entity. Consultant has not entered into and Consultant
shall not enter into any agreement, either written or oral, in conflict herewith or in conflict with Consultant’s engagement with
POINT.

 

2.5.         In the event that Consultant is required by order of a court, law, or regulation to disclose any of the Confidential Information,
Consultant shall promptly inform POINT of such requirement in writing so that POINT may seek a protective order or other appropriate
remedy. Consultant shall fully cooperate with POINT in connection with POINT’s efforts to obtain any such order or other remedy.
In the event that no such protective order or other remedy is obtained, or POINT waives compliance with the terms of this Agreement,
then, Consultant may: (a) furnish only that portion of the Confidential Information which Consultant is advised by counsel is legally
required; and (b) exercise best efforts to obtain reliable assurance that confidential treatment will be accorded to the Confidential
Information so disclosed.

 

2.6.         Consultant agrees to make and maintain adequate and current written records, in a form specified by POINT, of all Inventions,
trade secrets and works of authorship assigned or to be assigned to POINT pursuant to this Agreement during the Term and until
the expiration of five (5) years after the termination of Consultant’s engagement with POINT. Consultant agrees to make available,
upon written request of POINT or its designee, any records maintained by Consultant regarding any of the Consulting Services performed
hereunder by Consultant.

 

2.7.         Within thirty (30) days after termination or expiration of this Agreement, or at any time at POINT’s request, Consultant
shall: (a) at POINT’s cost and expense, return to POINT all Confidential
Information (in the medium provided by POINT).

    Page 2 of 10

     

    

		3.	Ownership
of Inventions

 

3.1.        Consultant shall promptly disclose in writing all Inventions to POINT. For purposes of this Agreement, “Inventions”
shall mean any invention or discovery that relates to, is based upon or arises as a result of use of any Confidential Information
of POINT and as a direct result of the Consulting Services and that is conceived or first reduced to practice during performance
of the Consulting Services.

 

3.2.        Consultant agrees and acknowledges that POINT shall solely own all right, title and interest in and to any and all Work
Product and Inventions which Consultant makes, discovers, conceives, reduces to practice or develops (in whole or in part, either
alone or jointly with others) during the Term, which arises directly from the provision of the Consulting Services.

 

3.3.        Consultant agrees that POINT shall be the sole owner of all patents, patent rights, copyrights, trade secret rights, trademark
rights and all other intellectual property or other rights in connection with the Work Product and Inventions directly arising
from the provision of the Consulting Services. Consultant hereby assigns, and agrees to assign, to POINT any and all rights, title
and interest Consultant may have or acquire in the future in such Work Product and Inventions and all applications related thereto.
If in the course of Consultant’s engagement with POINT, Consultant incorporates into a Work Product, a process, a prior Invention
or improvement whether or not related to the Consulting Services that is owned by Consultant, POINT is hereby granted and shall
have a non-exclusive, royalty- free, irrevocable, perpetual, sublicensable, worldwide license to make, have made, modify, use,
market, sell and distribute such prior Invention as part of, or in connection with, such product or process, unless otherwise agreed
to by the Parties in writing. Consultant also hereby waives, for the benefit of POINT and its successors and assigns, any and all
moral rights in respect of any Inventions and any work created, derived or arising from its work under this Agreement.

 

3.4.        Consultant agrees to perform, during and after the Term, all acts reasonably deemed necessary or desirable by POINT to permit
and assist it, at POINT’s expense at Consultant’s then- current rate plus reasonable costs and expenses, in further evidencing
and perfecting the assignments made to POINT under this Agreement and in obtaining, maintaining, defending and enforcing patents,
patent rights, copyrights, trademark rights, trade secret rights or any other rights in connection with such Inventions and improvements
related to the Consulting Services in any and all countries. Such acts may include, without limitation, execution of documents
and assistance or cooperation in legal proceedings. Consultant hereby irrevocably designates and appoints POINT and its duly authorized
officers and agents, as Consultant’s agents and attorney-in-fact, coupled with an interest, to act for and on Consultant’s behalf
and in Consultant’s place and stead, to execute and file any documents, applications or related findings and to do all other lawfully
permitted acts to further the purposes set forth above in this Section, including, without limitation, the perfection of assignment
and the prosecution and issuance of patents, patent applications, filings with a regulatory agency, copyright applications and
registrations, trademark applications and registrations or other rights in connection with such Inventions or Work Product and
improvements related to the Consulting Services with the same legal force and effect as if executed by Consultant.

 

Consultant
agrees, following the termination of Consultant’s engagement with POINT for any reason, to disclose immediately to
POINT Inventions related to PNT2001, PNT2002, PNT2003, PNT2004 and PNT2005, whether patentable or not, that (1) Consultant
conceives, reduces
to practice, or otherwise makes or develops, either solely or jointly with others, within six (6) months after the termination
of this Agreement; and (2) are in any way based on any trade secret or confidential or proprietary information that Consultant
learned during his engagement with POINT; or result from any work performed by Consultant for POINT under this Agreement; or are
in any way related to the subject matter or activities of Consultant’s engagement with POINT. Consultant agrees to assign to POINT,
without further compensation to Consultant, the entire title and rights to all such Inventions and applications related to the
Consulting Services that Consultant may have.

    Page 3 of 10

     

    

3.5.        No license, express or implied, by estoppel or otherwise, is granted by POINT to any intellectual property rights owned by or licensed
to POINT or any of its affiliates, licensors, or business collaborators.

 

		4.	Non-solicitation.

 

4.1.       
During the Term and for six (6) months thereafter, Consultant shall not encourage or solicit any employee of POINT to leave
POINT for any reason or to accept employment with Consultant or any other entity..

 

4.2.       
During the Term of this Agreement and for six (6) months thereafter, Consultant shall not interfere with or attempt to impair
the relationship between POINT and any of its non-employee consultants and advisors, nor shall Consultant attempt, directly or
indirectly, to solicit, entice, hire or otherwise by inducing any non-employee consultant or advisor of POINT to terminate association
with POINT.

 

		5.	Fees.

 

5.1.        As consideration for Consultant’s performance of the Consulting Services, POINT shall pay Consultant at the rate set out
in Schedule “B” hereto.

 

5.2.        POINT shall reimburse Consultant for customary out-of-pocket expenses amounts exceeding the amount set out in Schedule “B”
hereto must be pre-approved by an authorized POINT representative and incurred in furtherance of the Consulting Services upon presentation
of adequate supporting documentation (including without limitation, original accurate receipts).

 

5.3.        For services rendered, POINT shall pay invoices within thirty (30) days after receipt of each undisputed invoice and all
supporting documentation. POINT shall make all cheques payable to Consultant at the address specified in the invoice, unless otherwise
specified in writing.

 

5.4.        Consultant acknowledges and agrees that he/she shall be solely responsible for paying any and all national, federal, state,
provincial and local taxes with respect to all compensation paid to Consultant pursuant to this Agreement, and that POINT shall
have no responsibility whatsoever for withholding or paying any such taxes for or on behalf of Consultant.

 

5.5.        Consultant
shall be entirely responsible for and pay any and all wages, salaries, workers’ compensation premiums and other sums required
by law to be paid in connection with the Consulting Services.

    Page 4 of 10

     

    

5.6.        POINT
and Consultant acknowledge and agree that the compensation herein represents the fair market value for the Consulting Services,
has not been determined in a manner that takes into account the volume or value of any business otherwise generated between the
Parties, and shall not obligate Consultant to purchase, use, recommend, or arrange for the use of any product developed, manufactured,
or marketed by POINT, any of its business collaborators, or the formulary status of any products of POINT, any of its business
collaborators.

 

		6.	Warranties; Representations.

 

6.1.         Consultant represents, warrants, and covenants that:

 

(1)          the Consulting Services shall be performed: (i) using Consultant’s best efforts, expertise and skill; (ii) in a timely manner;
(iii) in accordance with the highest professional standards and quality; (iv) in accordance with all applicable laws, rules and
regulations; (v) in accordance with the terms and conditions this Agreement; and (vi) in a manner that shall not infringe, misappropriate,
or violate the rights of any third party.

 

(2)          Consultant has all the necessary licenses, permits or registrations to perform the Consulting Services in accordance with
the terms and conditions of this Agreement and that during the Term, all such licenses, permits or registrations are and shall
remain current and in good standing.

 

(3)          Consultant has (i) neither been debarred nor is otherwise subject to debarment proceedings, nor convicted of a crime for
which a person can be debarred under any applicable laws or regulations, disciplined by, excluded and/or banned by any relevant
regulatory agency; or (ii) excluded from any national or governmental payment program; and (iii) further agrees to immediately
notify POINT if any of the foregoing occurs. The foregoing may be relied on by POINT in any application to any applicable regulatory
agency for marketing approvals.

 

		7.	Term and Termination.

 

7.1.        This Agreement shall begin on the Effective Date and end December 31, 2021, unless terminated sooner as provided for herein
(the “Term”).

 

7.2.        In addition to the termination provision set forth in Section 1.1.4, POINT may terminate this Agreement: (i) without cause,
by providing the Consultant two (2) months’ prior written notice or pay in lieu of notice; and (ii) immediately upon occurrence
of any of the following events: (a) the breach of this Agreement by Consultant, which breach is not cured within ten (10) days
after written notice of such breach; (b) the dissolution, voluntary or involuntary bankruptcy of Consultant, or assignment by Consultant
of all or substantially all of its assets for the benefit of creditors; or (c) embezzlement, fraud or deceit in the performance
of Consultant’s obligations hereunder.

 

7.3.        If POINT terminates this Agreement, POINT shall pay Consultant for the actual work performed under the Consulting Services
and for Consultant’s actual costs incurred in connection with any non-cancellable commitments relating to the Consulting Services,
and Consultant shall use its best efforts to minimize such actual costs, and, in any event, the total amounts paid for the Consulting
Services shall not exceed the amount set forth in Schedule “B”. Consultant’s entitlement to an annual bonus or stock
options for time served, on a prorated basis if applicable, shall survive termination of this Agreement, as provided in Schedule
 “B”.

 

7.4.        Notwithstanding
the termination of this Agreement, any liability or obligation of either Party
which may have accrued prior to such termination shall continue in full force and effect, including but not limited to the rights
and obligations of the Parties hereto under Sections 2, 3, 4 and 7 of this Agreement.

    Page 5 of 10

     

    

		8.	Limitation of Liability and Indemnity

 

8.1.        In no event shall either Party be liable to the other for special, incidental or consequential damages arising under or as a result
of this Agreement (or termination thereof), including, but not limited to, the loss of prospective profits or on account of expenses,
investments, or commitments in connection with its business or goodwill or otherwise.

 

		9.	Notice.

 

9.1.
        All notices under this Agreement shall be deemed to have been fully given when done in writing and faxed to the other Party,
deposited in the regular mail, registered or certified, or sent overnight express courier, (receipt confirmed) and addressed
as follows:

 

	To POINT Pharma Corp.:	JOE MCCANN
	 	POINT Biopharma Inc.
	 	511 S. Orange Ave. #2093
	 	Newark, NJ 07103
	 	 
	 	Joe.McCann@pointbiopharma.com
	 	 
	To Consultant:	Attention: Dr Neil Fleshner
	 	610 University Ave
	 	Suite 30130
	 	Toronto, ON M5G 1Z5

    Page 6 of 10

     

    

		10.	Non-Assignment.

 

Consultant
agrees not to assign this Agreement or any of its rights and obligations hereunder without the express written consent of the
POINT, which consent shall not be unreasonably withheld.

 

		11.	Independent Contractor.

 

Consultant
acknowledges that it is performing the Consulting Services as an independent contractor and not as an agent, partner, joint-venturer
or employee of POINT for any purpose whatsoever, including without limitation, for purposes relating to taxes, payments required
by statute or any other withholdings or remittances to any governmental agency or authority. The Consultant does not have, nor
shall the Consultant hold himself out as having, any right, power or authority to create any contract or obligation, either express
or implied, on behalf of, in the name of, or binding upon POINT. Consultant shall not be entitled to rights or privileges applicable
to employees of POINT including, but not limited to, group insurance, pension plans, holidays, paid vacation which may be available
from time to time to POINT’s employees, whether or not this independent contractor relationship is determined by a court or any
tax or other governmental authorities to constitute an employment relationship.

 

		12.	Entire Agreement; Amendment.

 

12.1.      This Agreement and any and all exhibits, constitutes the entire agreement between the Parties and will not be changed or
affected by any previous agreements, whether oral or written, or any agreements of the same date. This Agreement supersedes all
other agreements, whether written or oral between the Parties regarding the subject matter hereof. Notwithstanding the foregoing,
however, any confidentiality agreement previously entered into between POINT or any of its affiliates or predecessors and Consultant
shall remain in effect in accordance with its terms. In the event of any conflict between the terms and conditions of this Agreement
and any such confidentiality agreement, the terms and conditions of this Agreement shall govern and control.

 

12.2.      This Agreement may not be amended, modified, superseded, canceled, or extended, except by a written instrument signed by
authorized representatives of the Parties.

 

		13.	Remedies.

 

In
the event of the actual or threatened breach by Consultant of Sections 2 or 3 of this Agreement, POINT shall be entitled to seek
injunctive relief to enforce the terms and conditions of this Agreement.

 

		14.	Choice of Law and Jurisdiction

 

This
Agreement shall be governed by and interpreted in accordance with the laws of the Province of Ontario, excluding the conflict of
law rules. The Parties hereto hereby submit to the non-exclusive jurisdiction of the courts of the Province of Ontario.

    Page 7 of 10

     

    

		15.	Severability; Waiver.

 

15.1.      Any provision of this Agreement which is found by a court of competent jurisdiction to be illegal or invalid shall be deemed
severed from this Agreement and shall not affect the continuing legality or validity of the rest of this Agreement.

 

15.2.      A waiver of any term, condition or default of this Agreement shall not be construed as a waiver of any other term, condition
or default.

 

		16.	Authorization.

 

Each
Party represents and warrants that the individuals signing this Agreement are authorized to do so and all necessary approvals and
authorizations have been made prior to the signing of this Agreement.

 

		17.	Counterparts.

 

This
Agreement may be executed and delivered by any means and in any number of counterparts, each of which shall be an original as against
either Party whose signature appears thereon, but all of which taken together shall constitute but one and the same instrument.
Any signature page delivered by facsimile or electronic image transmission, i.e. pdf, shall be binding to the same extent as an
original signature page.

 

The
Parties have executed this Agreement to be effective as of the Effective Date.

 

	POINT BIOPHARMA INC	 	Consultant	 
	 	 	 	 
	Signature:	/s/ Joe McCann	 	Signature:	/s/ Dr. Neil Fleshner
	Print Name:	Joe McCann	 	Print Name:	Dr Neil Fleshner
	Title:	CEO	 	Date:	03/09/2021
	Date:	03/08/2021	 	 	 

    Page 8 of 10

     

    

SCHEDULE “A”

 

DESCRIPTION
OF CONSULTING SERVICES

 

Chief
Medical Officer

 

The
Consultant is engaged for the purpose of providing the following:

 

		1.	Working with the Executive team, Board and counsel to
ensure the completion of POINT’s due diligence exercises

		2.	Be available to participate in presentations to investors
and answer verbal and written questions

		3.	Address patient safety and trial design questions on
behalf of the Clinical Development department

		4.	Product labeling questions based on emerging data, e.g.
safety profile of pipeline candidates

		5.	Participate in analyst meetings and reports to public
markets

		6.	Actively participate and support financing transactions

		7.	Participate in scientific discussions, clinical trial
designs and development and licensing opportunities

		8.	Participate as a Director on POINT’s Board of Directors

 

The
Consultant possesses the knowledge in the area of Medical and is willing to act as consultant, and POINT desires to engage the
Consultant to provide consulting services related to such knowledge. The Consultant will in his best efforts and ability to the
performance of the duties set forth herein. All work performed by the Consultant for POINT shall be at times reasonably convenient
to the Consultant.

     

     

    

SCHEDULE
 “B” - FEES

 

	Description of Services: 	 	Chief Medical Officer Consultant 

 

	Location:	 	Toronto, Ontario

 

	Fees:	 	CAD $10,416 per month for time spent plus HST.

 

	Performance:	 	In addition to your monthly fees you will be
eligible for an annual bonus of up to 25% of your annual fees ($125,000 CDN).

 

	 	 	If the Board, in its sole discretion, determines that the Company has met its short-term
and long-term business performance objectives and that you have met your personal performance objectives (together, the “Objectives”),
which Objectives will be established on an annual basis by the CEO and Board (or the Company’s Compensation Committee)
in consultation with you. Payment of the performance bonus (less all applicable statutory deductions by the Company) will be made
to you once approved by the Board (or Company’s Compensation Committee), and within 30 days after the Board has approved
the corporate yearend financial statements. You acknowledge that participation in any incentive or bonus plan during any one year
confers no rights upon you or any obligations on the Company to continue the plan or entitle you to participate in the plan in
succeeding years. Notwithstanding the foregoing, the Consultant’s entitlement to receive an annual bonus for time served
will survive termination of this Agreement, on a pro rata basis should the Agreement be terminated prior to the end of the Term.

 

	Expenses	 	Subject to the terms and conditions of the Option Agreement and at the approval of the Board
of Directors, you may be entitled to receive an annual performance-based allocation of stock options in the Company equivalent
in shares to [20 % of your salary, i.e. $125,000 X 20% = 25,000 shares. Notwithstanding the foregoing, the Consultant’s
entitlement to receive stock options for time served will survive termination of this Agreement, on a pro rata basis should the
Agreement be terminated prior to the end of the Term.

 

	 	 	POINT shall reimburse Consultant for expenses incurred by Consultant in performing services.
All individual expenses in excess of $500 must be approved in writing by a representative of POINT. Presentation of adequate supporting
documentation (including without limitation, original accurate receipts) may be required.

 

	 	 	Expenses may include specific project supplies, travel, lodging, meals and incidental costs
for work at locations other than Consultant’s office in Toronto, Ontario.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]